Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China
- PMID: 32317180
- PMCID: PMC7166037
- DOI: 10.1016/j.eururo.2020.03.039
Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China
Abstract
Background: Previous studies on coronavirus disease 2019 (COVID-19) have focused on populations with normal immunity, but lack data on immunocompromised populations.
Objective: To evaluate the clinical features and outcomes of COVID-19 pneumonia in kidney transplant recipients.
Design, setting, and participants: A total of 10 renal transplant recipients with laboratory-confirmed COVID-19 pneumonia were enrolled in this retrospective study. In addition, 10 of their family members diagnosed with COVID-19 pneumonia were included in the control group.
Intervention: Immunosuppressant reduction and low-dose methylprednisolone therapy.
Outcome measurements and statistical analysis: The clinical outcomes (the severity of pneumonia, recovery rate, time of virus shedding, and length of illness) were compared with the control group by statistical analysis.
Results and limitations: The clinical symptomatic, laboratory, and radiological characteristics of COVID-19 pneumonia in the renal transplant recipients were similar to those of severe COVID-19 pneumonia in the general population. The severity of COVID-19 pneumonia was greater in the transplant recipients than in the control group (five severe/three critical cases vs one severe case). Five patients developed transient renal allograft damage. After a longer time of virus shedding (28.4 ± 9.3 vs 12.2 ± 4.6 d in the control group) and a longer course of illness (35.3 ± 8.3 vs 18.8 ± 10.5 d in the control group), nine of the 10 transplant patients recovered successfully after treatment. One patient developed acute renal graft failure and died of progressive respiratory failure.
Conclusions: Kidney transplant recipients had more severe COVID-19 pneumonia than the general population, but most of them recovered after a prolonged clinical course and virus shedding. Findings from this small group of cases may have important implications for the treatment of COVID-19 pneumonia in immunosuppressed populations.
Patient summary: Immunosuppressed transplant recipients with coronavirus disease 2019 infection had more severe pneumonia, but most of them still achieved a good prognosis after appropriate treatment.
Keywords: Coronavirus disease 2019; Immunosuppression; Kidney transplantation; Outcome; Pneumonia.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Figures
Comment in
-
Re: Lan Zhu, Nianqiao Gong, Bin Liu, et al. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China. Eur Urol 2020;77:748-54.Eur Urol. 2020 Oct;78(4):e158. doi: 10.1016/j.eururo.2020.06.058. Epub 2020 Jul 4. Eur Urol. 2020. PMID: 32660746 Free PMC article. No abstract available.
Similar articles
-
COVID-19 in a Kidney Transplant Patient.Eur Urol. 2020 Jun;77(6):769-770. doi: 10.1016/j.eururo.2020.03.036. Epub 2020 Apr 6. Eur Urol. 2020. PMID: 32273181 Free PMC article. No abstract available.
-
Identification of Kidney Transplant Recipients with Coronavirus Disease 2019.Eur Urol. 2020 Jun;77(6):742-747. doi: 10.1016/j.eururo.2020.03.030. Epub 2020 Apr 2. Eur Urol. 2020. PMID: 32249089 Free PMC article.
-
A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.Kidney Int. 2020 Jun;97(6):1083-1088. doi: 10.1016/j.kint.2020.04.002. Epub 2020 Apr 9. Kidney Int. 2020. PMID: 32354634 Free PMC article.
-
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.Ther Drug Monit. 2020 Jun;42(3):360-368. doi: 10.1097/FTD.0000000000000761. Ther Drug Monit. 2020. PMID: 32304488 Free PMC article. Review.
-
BET 1: Lopinavir-ritonavir and COVID-19.Emerg Med J. 2020 Jul;37(7):450-451. doi: 10.1136/emermed-2020-210221.2. Emerg Med J. 2020. PMID: 32616658 Review. No abstract available.
Cited by
-
Covid-19 in end-stage renal disease patients with renal replacement therapies: A systematic review and meta-analysis.PLoS Negl Trop Dis. 2021 Jun 15;15(6):e0009156. doi: 10.1371/journal.pntd.0009156. eCollection 2021 Jun. PLoS Negl Trop Dis. 2021. PMID: 34129609 Free PMC article.
-
Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients.Transplantation. 2021 Oct 1;105(10):2175-2183. doi: 10.1097/TP.0000000000003860. Transplantation. 2021. PMID: 34149003 Free PMC article.
-
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.Biochem Pharmacol. 2021 Jan;183:114296. doi: 10.1016/j.bcp.2020.114296. Epub 2020 Oct 22. Biochem Pharmacol. 2021. PMID: 33191206 Free PMC article. Review.
-
COVID-19 Mortality in Transplant Recipients.Int J Organ Transplant Med. 2020;11(4):145-162. Int J Organ Transplant Med. 2020. PMID: 33335696 Free PMC article. Review.
-
Recovery of new-onset kidney disease in COVID-19 patients discharged from hospital.BMC Infect Dis. 2021 Apr 29;21(1):397. doi: 10.1186/s12879-021-06105-8. BMC Infect Dis. 2021. PMID: 33926392 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical